| | |
| DON'T BUY | 0.670 | Robert McWhirter | At the bottom end of his database. Reported 9% negative earnings. Last $.35 in 2006. Great technology, but it seems to be taking forever to get it out into the marketplace. | 2006-08-15 | |
| | |
| BUY | 1.700 | Robert McWhirter | This stock is at the bottome 15% of the database. Long on promise short on delivery type of company. They have tests for Avian flu and genetic tests for newborns. Signed up a large number of testing facilities in the U.S, but this is only used in a small range. He has owned in the past but does not own currently. If Avian flu passes to humans this company would benefit. | 2006-03-13 | |
| | |
| DON'T BUY | 2.120 | Robert McWhirter | Quest (DGX-N) has done a "toe-in-the-water" on their product giving them a limited exposure to it. Was the product successful and will Quest and others broaden out their purchases? Very interesting product. Ranks poorly in his overall model at this point. | 2005-07-21 | |
| | |
| WEAK BUY | 2.250 | Robert McWhirter | Speculative. Good technology. Less expensive technologies. | 2004-07-09 | |
| | |
| BUY | 0.580 | Hugh McCauley | Very volatile. Have a tiny percentage in a couple of their funds. Have superior technology in genetic testing. An early stage company. Should see breakeven by the end of the year. | 2004-05-13 | |
| | |
| BUY | 0.480 | Robert McWhirter | Trades in a band of $.40 to $.50. They have a methodology which should be quite powerful for them in 2004. Have a one-year lead over Pfizer. Speculative but pretty good prospects. | 2004-02-12 | |
| | |
| BUY on WEAKNESS | 1.000 | Glenn Paradis, BA, CFA | In a good area Too speculative Watch for new clients | 2000-10-13 | |
Experts that have talked about TM Bioscience
Rss Top Picks Feed